Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
AFT Leaves X Over AI-Generated Images of Minors 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
IRVINE, Calif., April 03, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against NantHealth, Inc. (“NantHealth” or the “Company”) (Nasdaq:NH). Investors who purchased shares (1) pursuant and/or traceable to the Company’s initial public offering (“IPO”) on or about June 1, 2016; and/or (2) between June 1, 2016 and March 6, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the May 8, 2017 lead plaintiff motion deadline.
If you purchased shares of NantHealth during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint states that during the Class Period, NantHealth made materially false and/or misleading statements and/or failed to disclose: that its founder Patrick Soon-Shiong had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; that NantHealth and Soon-Shiong violated federal tax laws; that the Company improperly recorded orders received from the University of Utah as GPS Cancer test orders; and that the Company reported false and inflated GPS Cancer order figures for the third quarter of 2016. When this information reached the public, shares of NantHealth dropped in value, thus harming investors.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
